Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2009

View Archived Issues

Inotek reports results from phase I/II clinical trial of INO-8875 in glaucoma

Boehringer Ingelheim discloses CGRP antagonists for the treatment of migraine

Abbott describes novel vitamin D receptor activators for the treatment of bone disorders

LB-03002 significantly reduces fat mass in adults with growth hormone deficiency

Phase III data on 13-valent vaccine show coverage against pneumococcal disease

Secondary leukemias seen with ibritumomab in indolent/aggressive lymphoma patients

Small study suggests donepezil can improve sleep apnea

Antisense Therapeutics completes CSR for phase IIa clinical trial of ATL/TV1102 in MS

Sorafenib beneficial in phase II differentiated thyroid carcinoma trial

Evotec completes phase I study of EVT-401 in healthy male volunteers

FEVER trial analysis shows reduced cardiovascular event risk in lower-risk patients with felodipine

Ardea Biosciences' MEK inhibitors show efficacy in arthritis model

Takeda submits additional indication and NDA applications for alogliptin

Achillion starts dosing in first-in-human ACH-1625 trial for hepatitis C

Innate reports phase IIa results for IPH-1101 in hepatitis C virus infection

CSL to commence trial of novel H1N1 swine flu candidate vaccine

Biolex completes enrollment in SELECT-2 phase IIb Locteron trial in HCV

AcelRx presents phase II results from ARX-01 Sufentanil NanoTabs trial in pain

Cephalon submits Nuvigil sNDA for sleepiness associated with jet lag disorder

Pozen submits NDA for PN-400 in collaboration with AstraZeneca

Ablynx advances ALX-0061 into preclinical development for autoimmune diseases

Novartis initiates phase III clinical study of NVA-237 in COPD

AlphaRx and Gaia report preclinical results from studies of GAI-122 for postoperative delirium

Vantia reports results from phase IIa clinical trial of VA-106483 in nocturia

Palkion initiates preclinical development of anemia drug that modulates HIF-PH

FDA granted marketing approval for AMAG's Feraheme in chronic kidney disease